Alkandari Mohammad H, Touma Nawar, Carrier Serge
McGill University Health Center, Department of Surgery, Division of Urology, Montreal, Quebec, Canada.
McGill University, Montreal, Quebec, Canada.
Sex Med Rev. 2022 Apr;10(2):341-352. doi: 10.1016/j.sxmr.2020.12.004. Epub 2021 Jul 2.
Erectile Dysfunction (ED) and Peyronie's Disease (PD) are debilitating medical conditions affecting patients' quality of life (QoL). Platelet-rich plasma (PRP) injections are one of the various emerging approaches proposed to treat these medical conditions.
To describe the evidence of the potential role of PRP injections in ED and PD.
The authors conducted a systematic review according to the PRISMA statement using the following databases in November 2019: The National Library of Medicine (PubMed), Ovid Medline, Cochrane, Scopus, Embase, and Embase classic. The search was performed using keywords drawn from studies on the use of PRP in ED and PD in clinical and preclinical studies.
Eighteen articles met the inclusion criteria for review, including 12 studies on the use of PRP in humans and 6 on the use of PRP in rats. Ten studies reported on the efficacy of PRP in ED exclusively, 7 in PD exclusively and one in both conditions. In humans, 6 and 3 studies showed promising results in PD and ED, respectively. No major complications were noted. Unwanted minor side effects were noted by studies reporting on PD, including mild penile bruising, ecchymosis, hematomas as well as transient hypotension noted in 2 out of 90 patients.
PRP injections for the treatment of ED may be promising, but no recommendation can be made because of scarce evidence. Safety and effectiveness of this therapy in the treatment of ED and PD require further preclinical and clinical studies with standardized protocols to gain an adequate insight into its potential implications. Patients should be offered to be part of such trials to better understand PRP potential. Alkandari MH, Touma N, Carrier S, Platelet-Rich Plasma Injections for Erectile Dysfunction and Peyronie's Disease: A Systematic Review of Evidence. Sex Med Rev 2022;10:341-352.
勃起功能障碍(ED)和佩罗尼氏病(PD)是影响患者生活质量(QoL)的使人衰弱的病症。富血小板血浆(PRP)注射是为治疗这些病症而提出的各种新兴方法之一。
描述PRP注射在ED和PD中潜在作用的证据。
作者根据PRISMA声明,于2019年11月使用以下数据库进行了系统评价:美国国立医学图书馆(PubMed)、Ovid Medline、Cochrane、Scopus、Embase和Embase经典数据库。搜索使用了从临床和临床前研究中关于PRP在ED和PD中的应用研究中提取的关键词。
18篇文章符合纳入标准以供综述,其中包括12项关于人类使用PRP的研究和6项关于大鼠使用PRP的研究。10项研究专门报道了PRP在ED中的疗效,7项专门报道了在PD中的疗效,1项报道了在两种病症中的疗效。在人类研究中,分别有6项和3项研究在PD和ED中显示出有前景的结果。未发现重大并发症。报道PD的研究指出了一些轻微的不良副作用,包括轻度阴茎瘀伤、瘀斑、血肿,以及90名患者中有2名出现短暂性低血压。
PRP注射治疗ED可能具有前景,但由于证据不足无法给出推荐。该疗法在治疗ED和PD中的安全性和有效性需要进一步开展采用标准化方案的临床前和临床研究,以充分了解其潜在影响。应让患者参与此类试验,以便更好地了解PRP的潜力。Alkandari MH、Touma N、Carrier S,《用于勃起功能障碍和佩罗尼氏病的富血小板血浆注射:证据的系统评价》。《性医学评论》2022年;10:341 - 352。